This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott's (ABT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The downside can be attributed to a manufacturing disruption during 2022 of certain infant formula products at Abbott's (ABT) Sturgis, MI facility.
NextGen (NXGN) Q3 Earnings Fall Shy of Estimates, Revenues Top
by Zacks Equity Research
NextGen's (NXGN) third-quarter fiscal 2023 results reflect strength in its Recurring revenues.
Intuitive Surgical (ISRG) Falls Following Q4 Earnings Miss
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales and unfavorable currency. Procedure volume in China suffers.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
McKesson (MCK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $376.50 in the latest trading session, marking a +0.39% move from the prior day.
Quest Diagnostics (DGX) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics (DGX) ramps up investments to accelerate growth in the base business, particularly in advanced diagnostics and direct-to-consumer testing.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter results are likely to reflect its strong segmental performances. However, rising costs are likely to have continued to have hurt margins during the quarter.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q4 owing to continued rise in Catalyst and premium hematology placements.
Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q1 Earnings
by Zacks Equity Research
The growing adoption of Panther instruments worldwide will likely drive Hologic's (HOLX) Q1 revenues.
Intuitive Surgical (ISRG) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
McKesson (MCK) Stock Moves -1.32%: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $378.40, moving -1.32% from the previous trading session.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) increased shipments in Invisalign case volumes across almost all markets are likely to benefit Q4 revenues.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI), owing to its strong product portfolio.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the increasing adoption of the da Vinci Surgical System. Improving margins buoy optimism.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growing adoption of Panther instruments and growth in the Surgical business will likely drive Hologic's (HOLX) Q1 revenues.
Is Laboratory Corp. of America (LH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Zacks.com featured highlights DCP Midstream Partners, Herc Holdings, MRC Global and McKesson
by Zacks Equity Research
DCP Midstream Partners, Herc Holdings, MRC Global and McKesson have been highlighted in this Screen of The Week article.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like HRI, DCP, MRC and MCK that are seeing price strength have a high chance of carrying the momentum forward.
McKesson (MCK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $381.96 in the latest trading session, marking a -1.06% move from the prior day.
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Doctor Reddy's (RDY) have performed compared to their sector so far this year.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.